Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (153)	12/18/2002 4:34:12 PM
From: Jibacoa	Respond to of 3722

ILXO Although it showed some weakness towards the closing, it was up 7.95% on volume of 480K (more than 2x its daily average.) It announced early today that it will sublicense CAMPATH related diagnostic testing rights for Europe, the Middle East and Israel to BioAnaLab. It was also announced at the ASH meeting in Philadelphia the results of Phase II open label trial of clofarabine. (Clofarabine has been granted Orphan Drug Status in both Europe and the US and is a product of BIOV for which ILXO is conducting the Phase II trial.) Out of 31 relapsed/refractory AML patients enrolled in the study, 13 achieved a complete remission (CR) and 4 achieved a complete remission with low platelet count but were platelet transfusion independent (CRp). This amounted to an overall response rate of 55%. biz.yahoo.com ILXO Seems to have support at the 7 level, but it is still somewhat far from its November 25 H of 11.20 <g> siliconinvestor.com Bernard